It remains unclear whether myocardial signal alterations or cardiac functional changes at CMR in asymptomatic carriers of pathogenic TTR mutations precede overt clinical signs of systemic amyloidosis. The gene discussed is TTR; the disease is primary systemic amyloidosis.